Safety profile of tiotropium add-on therapy in paediatric patients by gender

C. Vogelberg (Dresden, Germany), E. Hamelmann (Bielefeld, Germany), M. Engel (Ingelheim am Rhein, Germany), G. El Azzi (Ingelheim am Rhein, Germany), S. Vulcu (Ingelheim am Rhein, Germany), S. Szefler (Aurora, United States of America)

Source: International Congress 2018 – Innovative therapies in asthma and COPD
Session: Innovative therapies in asthma and COPD
Session type: Poster Discussion
Number: 608
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Vogelberg (Dresden, Germany), E. Hamelmann (Bielefeld, Germany), M. Engel (Ingelheim am Rhein, Germany), G. El Azzi (Ingelheim am Rhein, Germany), S. Vulcu (Ingelheim am Rhein, Germany), S. Szefler (Aurora, United States of America). Safety profile of tiotropium add-on therapy in paediatric patients by gender. 608

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006

1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014



Efficacy and safety of once-daily single-inhaler triple therapy in patients with inadequately controlled asthma: the CAPTAIN trial
Source: Breathe, 17 (1) 200279; 10.1183/20734735.0279-2020
Year: 2021



Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008

Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma
Source: International Congress 2016 – Living with asthma around the globe
Year: 2016


Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials
Source: Annual Congress 2012 - Different ways to phenotype asthma
Year: 2012



Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


High-dose inhaled corticosteroids and add-on therapy use in adults in the UK: an observational study of 22,027 patients
Source: Annual Congress 2004 - Primary care: asthma
Year: 2004


Efficacy of tiotropium and olodaterol fixed-dose combination in patients with COPD on β-blockers
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013

Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients
Source: Eur Respir J, 53 (6) 1801824; 10.1183/13993003.01824-2018
Year: 2019



Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

The use of high-dose inhaled corticosteroids and add-on therapy in children in the UK: an observational study of 4332 patients
Source: Annual Congress 2004 - New aspects of drug therapy in paediatric asthma
Year: 2004


Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Efficacy and tolerability of ciclesonide (CIC) in the treatment of 24,037 asthmatic patients in routine clinical care
Source: Annual Congress 2010 - Pharmacological treatment in primary care
Year: 2010